Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.Rev Med Virol. 2020 Sep; 30(5):e2136.RM
Abstract
SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.
Links
MeSH
Adenosine MonophosphateAlanineAngiotensin-Converting Enzyme 2Antibodies, Monoclonal, HumanizedAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsDisease ProgressionDrug CombinationsDrug RepositioningEstersGabexateGene Expression RegulationGuanidinesHost-Pathogen InteractionsHumansHydroxychloroquineIndolesLopinavirPandemicsPeptidyl-Dipeptidase APneumonia, ViralRitonavirSARS-CoV-2Spike Glycoprotein, Coronavirus
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
32644275
Citation
Giovane, Richard A., et al. "Current Pharmacological Modalities for Management of Novel Coronavirus Disease 2019 (COVID-19) and the Rationale for Their Utilization: a Review." Reviews in Medical Virology, vol. 30, no. 5, 2020, pp. e2136.
Giovane RA, Rezai S, Cleland E, et al. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Rev Med Virol. 2020;30(5):e2136.
Giovane, R. A., Rezai, S., Cleland, E., & Henderson, C. E. (2020). Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in Medical Virology, 30(5), e2136. https://doi.org/10.1002/rmv.2136
Giovane RA, et al. Current Pharmacological Modalities for Management of Novel Coronavirus Disease 2019 (COVID-19) and the Rationale for Their Utilization: a Review. Rev Med Virol. 2020;30(5):e2136. PubMed PMID: 32644275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
AU - Giovane,Richard A,
AU - Rezai,Shadi,
AU - Cleland,Ellen,
AU - Henderson,Cassandra E,
Y1 - 2020/07/09/
PY - 2020/4/30/received
PY - 2020/6/1/revised
PY - 2020/6/2/accepted
PY - 2020/7/10/pubmed
PY - 2020/10/2/medline
PY - 2020/7/10/entrez
KW - 2019-nCoV
KW - COVID-19
KW - Lopinavir/Ritonavir
KW - RNA-dependent RNA polymerase inhibitors
KW - Remdesivir
KW - SARS CoV-2
KW - SARS coronavirus (SARS-CoV)
KW - Umifenovir
KW - acetazolamide
KW - acute respiratory distress syndrome (ARDS)
KW - autoimmune
KW - camostat mesylate
KW - chloroquine
KW - high altitude pulmonary edema (HAPE)
KW - hydroxychloroquine
KW - novel coronavirus 2019
KW - pandemic
KW - severe acute respiratory syndrome (SARS)
SP - e2136
EP - e2136
JF - Reviews in medical virology
JO - Rev Med Virol
VL - 30
IS - 5
N2 - SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.
SN - 1099-1654
UR - https://www.unboundmedicine.com/medline/citation/32644275/Current_pharmacological_modalities_for_management_of_novel_coronavirus_disease_2019__COVID_19__and_the_rationale_for_their_utilization:_A_review_
DB - PRIME
DP - Unbound Medicine
ER -